questionText: To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the (a) pricing and (b) reimbursement system for multi-indication medicines is adequate for patients with (i) rare and (ii) ultra-rare conditions.
answerText: Indication-specific pricing can support access to treatments, including for rare conditions, by enabling companies to propose a specific price for smaller indications that would otherwise be commercially unviable under a uniform price.In January 2025, fol...
heading: Rare Diseases: Drugs